Recursion Appoints Vicki Goodman as CMO Effective April 6, Taps 20 Years Oncology Leadership
Recursion will appoint Vicki Goodman, M.D., effective April 6, 2026, as chief medical officer, replacing David Mauro. Goodman brings over two decades of oncology leadership, including CMO roles at Mural Oncology and Exelixis, oversight of KEYTRUDA and OPDIVO development, as Recursion advances REC-4881 and other clinical-stage programs.
1. CMO Appointment and Timing
Recursion will appoint Vicki Goodman, M.D., as Chief Medical Officer effective April 6, 2026, as current CMO David Mauro transitions out after three years in the role to pursue other opportunities.
2. Goodman's Oncology Leadership
Dr. Goodman brings over 20 years of oncology drug development experience, including CMO roles at Mural Oncology and Exelixis, oversight of KEYTRUDA and OPDIVO programs at Merck and Bristol Myers Squibb, and leadership in clinical expansion and regulatory approval at GlaxoSmithKline and the FDA.
3. Pipeline Advancement and Mauro's Contributions
Goodman will guide key clinical and regulatory inflection points across Recursion's portfolio, including progression of REC-4881, while Mauro, credited with strengthening the medical organization and advancing clinical programs, will support a smooth transition before his departure.